UBS Raises BrightSpring Health Services Price Target to $92
UBS reiterated its Buy rating and raised its price target from $85 to $92. The change follows the company's third-quarter report, which highlighted revenue growth and raised guidance.
UBS reiterated its Buy rating and raised its price target from $85 to $92. The change follows the company's third-quarter report, which highlighted revenue growth and raised guidance.